Taylor Robichaux/LinkedIn
Jan 9, 2026, 07:07
Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
Taylor Robichaux, Emergency Medicine Clinical Pharmacist at Ochsner LSU Health, shared on LinkedIn:
”The landscape for cTTP is evolving!
Check out our paper on recombinant ADAMTS13 in JADPRO!
It was a privilege to work with such a great group of pharmacists.
Congratulations to all the authors!”
Read the full article here.
Article: Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura
Authors: Taylor Robichaux, Kathryn Dane, Christopher Parish, Justin Arnall, Donald Moore
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial